The latest financial statement is for the quarter ending 2026-03-31.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -40,591 | -42,459 | -100,984 | - |
| Depreciation and amortization expense | 49 | 57 | 131 | - |
| Stock-based compensation expense | 4,647 | 2,506 | 7,826 | - |
| Change in fair value of preferred stock tranche right liability | - | 0 | - | - |
| Net amortization of premiums and accretion of discounts on short-term investments | 754 | -1,372 | 2,874 | - |
| Non-cash lease expense | 151 | 146 | 415 | - |
| Accounts receivable | 366 | -15 | 70 | - |
| Prepaid expenses and other assets | 11,046 | -6,287 | 7,811 | - |
| Accounts payable | -1,016 | -1,226 | -55 | - |
| Accrued expenses and other current liabilities | 1,229 | 2,821 | 1,193 | - |
| Operating lease liabilities | -155 | -150 | -415 | - |
| Net cash used in operating activities | -47,852 | -30,631 | -102,644 | - |
| Purchases of short-term investments | 14,422 | 38,282 | 347,596 | - |
| Maturities of short-term investments | 56,822 | 97,278 | 195,285 | - |
| Purchases of equipment | - | 54 | 111 | - |
| Net cash provided by (used in) investing activities | 42,400 | 58,942 | -152,422 | - |
| Proceeds from the issuance of series b redeemable convertible preferred stock, net of issuance costs paid | - | 0 | - | - |
| Proceeds from initial public offering, net of underwriters discounts and commissions | - | 0 | - | - |
| Payments of deferred offering costs | - | - | 34 | - |
| Payments of initial public offering costs | 0 | 34 | - | - |
| Proceeds from exercises of stock options | 598 | 907 | 1,372 | - |
| Proceeds from issuance of common stock under employee stock purchase plan | - | 196 | - | - |
| Net cash provided by (used in) financing activities | 598 | 1,103 | 1,338 | - |
| Restricted cash | - | - | - | 194 |
| Net decrease in cash, cash equivalents and restricted cash | -4,854 | 29,414 | -253,728 | - |
| Cash and cash equivalents | - | - | - | 45,458 |
| Cash, cash equivalents and restricted cash at beginning of period | 101,772 | 72,358 | 45,652 | - |
| Total cash, cash equivalents and restricted cash at end of period | - | - | - | 45,652 |
| Cash, cash equivalents and restricted cash at end of period | 96,918 | 101,772 | 72,358 | - |
Upstream Bio, Inc. (UPB)
Upstream Bio, Inc. (UPB)